EYLEA® (aflibercept) Injection is a prescription medicine administered by injection into the eye. You should not use EYLEA if you have an infection in or around the eye, eye pain or redness, or known allergies to any of the ingredients in EYLEA, including aflibercept.
Important: Help to manage your eye health during the COVID-19 pandemic. Learn more >
What is Diabetic Retinopathy (DR), and what can it do to your eyes?
Diabetic Retinopathy is the leading cause of new cases of blindness in people 20 to 74 years of age in the United States. DR is the most common diabetic eye disease and can lead to vision loss—but early detection, timely treatment, and appropriate follow-up care may help reduce the severity of the disease.
Diabetic Macular Edema (DME) is a complication of DR, and can lead to further vision problems.
DR happens when too much blood sugar (glucose) damages the blood vessels in the retina. As a result:
Throughout the early stages of Diabetic Retinopathy, existing blood vessels in the eye can become swollen and blocked, and leak blood and fluid into the retina—though there may be no visual symptoms.
Diabetic Retinopathy can get worse over time, particularly if it's not managed. In the moderate stages, the bleeding continues and visual symptoms may begin to appear.
If Diabetic Retinopathy progresses into its most advanced stage (proliferative), an increased growth of new blood vessels occurs. These new blood vessels are fragile and easily damaged—which adds to the swelling and leaking.
DME is a complication of DR, and occurs if the macula, the area of the retina at the back of the eye responsible for sharp central vision, swells with fluid leaked from those damaged blood vessels. You can learn more about DME here.
With DR, you may not experience any symptoms at first. But as the disease progresses, it can affect both central vision and peripheral (side) vision—causing symptoms like blurriness or floating spots in your vision (floaters).
It’s important to remember that even if no symptoms are present, early detection and timely treatment can go a long way to reduce the severity of DR. Learn more about the stages of DR and how EYLEA may be able to help.
If you have diabetes, a dilated eye exam can detect changes in your vision—and can help diagnose DR before symptoms appear. Don't wait. Be sure to get a dilated eye exam at least once a year. Also be sure to follow up with your eye doctor on a regular basis.
DR may lead to vision loss. However, you can take important steps to help your vision.
Your eye care team can help you manage your eye health and treat your eye condition. Make sure you are taking full advantage of your appointments with our preparation tips.
Looking for a specialist who treats DR? Use our tool to find one near you.
Not sure what to ask during your next appointment? Our doctor discussion guide can give you some ideas.
EYLEA has been studied in more than 3,000 people with certain diseases of the retina. Learn more about the #1 prescribed FDA-approved anti-vascular endothelial growth (anti-VEGF) factor treatment for patients with DR in DME.*
*IBM Truven MarketScan data: Number of injections administered, from Oct. 2017 through Sept. 2018; Data on File.
EYLEA is a prescription medicine given by injection into the eye. You should not use EYLEA if you have an infection in or around the eye, eye pain or redness, or known allergies to any of the ingredients in EYLEA, including aflibercept.
Get the latest materials and communications about EYLEA—and a complimentary pocket magnifier, too.
Just a few changes may make a big difference in your daily routine.
DME is a complication of DR, which occurs when DR affects the macula.
You are encouraged to report negative side effects of prescription drugs to the FDA.
Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
EYLEA® (aflibercept) Injection 2 mg (0.05mL) is a prescription medicine approved for the treatment of patients with Wet Age-related Macular Degeneration (AMD), Macular Edema following Retinal Vein Occlusion (RVO), Diabetic Macular Edema (DME), and Diabetic Retinopathy (DR).
Please see the full Prescribing Information for EYLEA.
The information contained herein is provided for general educational purposes. If you have any questions, talk to your doctor.
For U.S. Residents Only
EYLEA AND EYLEA4U are registered trademarks of Regeneron Pharmaceuticals, Inc.
© 2021, Regeneron Pharmaceuticals, Inc. All rights reserved.
777 Old Saw Mill River Road,
Tarrytown, NY 10591
04/2021
EYL.21.04.0042 EYL.21.04.0042
Searching with Lea
YOU ARE ABOUT TO LEAVE EYLEA.US.
You will be leaving this Regeneron U.S. website and going to a third-party independent website. Regeneron provides these links for your information only and takes no responsibility for the content on any such website.
ARE YOU A HEALTHCARE PROFESSIONAL?
This section of the EYLEA website is for healthcare professionals only.
YOU ARE ABOUT TO LEAVE EYLEA.US.
By clicking on this link, you will be leaving this Regeneron U.S. website and going to another Regeneron website.
COOKIE NOTICE
This website sets cookies on your computer, to give you the best experience by personalizing your content and analyzing traffic. Without cookies, the site won’t function as expected. If you want to learn more, please read our Privacy Policy or Cookies Policy. By closing this message, you consent to the use of cookies on this device.
